(Reuters) – Medtronic Plc beat Wall Street estimates for quarterly profit on Thursday, helped by a recovery in non-urgent surgical procedures that were delayed during the pandemic as well as strong demand for its heart and diabetes devices.
Excluding items, the Dublin-based medical device maker reported a profit of $1.57 per share for the fourth quarter, slightly above analysts’ average estimate of $1.56 per share, according to Refinitiv IBES data.
(Reporting by Bhanvi Satija and Raghav Mahobe in Bengaluru; Editing by Shweta Agarwal)
